Targets

TROP2

4 articles

Medicinal ChemistryJournal of Medicinal Chemistry (ACS)

AI-Designed Mini-Proteins Replace Antibodies as TROP2-Targeting Drug Carriers for Solid Tumors

  • Deep-learning design produced a small protein binder against the tumor antigen TROP2, avoiding animal immunization and antibody screening.
  • The binder showed good specificity and thermal stability, and partial diffusion sharpened its affinity by roughly sixty-fold.
  • Attaching the microtubule-disrupting payload VcMMAE yielded mini-protein drug conjugates that selectively kill TROP2-positive cancer cells.
  • Activity was assessed in cell lines, organoids and mouse xenografts.
PointsBased on the abstract

A de novo binder skips immunization, but an ADC carrier lives or dies on pharmacokinetics: without an Fc or albumin-binding handle, a mini-protein clears through the kidney fast, and a vcMMAE payload will raise renal and hydrophobicity-driven uptake concerns. I'd want half-life, kidney accumulation and TROP2-negative tissue data, plus a head-to-head against sacituzumab-type ADCs, before calling this an antibody replacement.

Industry NewsMerck / Kelun-BiotechEndpoints News

Merck's R&D Chief Says Breadth Gives sac-TMT the Edge in the TROP2 ADC Race

  • In an Endpoints interview, Merck R&D head Dean Li argued the company outflanked rivals on next-generation oncology by pushing sac-TMT, its Kelun-licensed TROP2 ADC, into a wide set of indications.
  • He pointed to the gynecologic and gastric cancer programs as where the drug has an advantage over competing TROP2 ADCs.
  • Context: sac-TMT recently posted a survival benefit in a Phase 3 endometrial cancer trial, which has FDA priority review.
PointsBased on public reports

Li is selling breadth as the moat: with TROP2 ADCs converging on lung and breast, Merck is trying to own tumor types where rivals are absent and where Keytruda combinations are natural. It is a sensible hedge against the Keytruda patent cliff, but the claim is an executive's own read, and it only holds if the gynecologic and gastric trials keep delivering.

Industry NewsMerck / Kelun-BiotechBioSpace

Sac-TMT Beats Chemo on Survival in Endometrial Cancer, a First for a TROP2 ADC

  • In the Phase 3 TroFuse-005 trial (about 776 patients), the TROP2 ADC sac-TMT from Merck and Kelun-Biotech outperformed chemotherapy in previously treated advanced or recurrent endometrial cancer.
  • Median overall survival reached 19.0 versus 12.1 months, and progression-free survival 7.2 versus 3.9 months.
  • Severe treatment-related adverse events were more common with the ADC (54.4% vs 41.4%). The FDA has granted priority review.
PointsBased on public reports

A 6.9-month overall survival gain over chemotherapy is a strong result in a TROP2 field where Gilead and Daiichi Sankyo/AstraZeneca already compete, and it gives sac-TMT randomized survival data to lean on. The 13-point gap in severe adverse events will shape its positioning. For Merck, it shows a China-originated ADC moving toward the center of its oncology pipeline.

Industry NewsSummit Therapeutics / AstraZeneca / Daiichi SankyoEndpoints News

Summit, AstraZeneca and Daiichi Sankyo to test ivonescimab plus Datroway, starting with Phase III in 1L TNBC

  • Summit, AstraZeneca and Daiichi Sankyo announced a clinical collaboration combining ivonescimab (PD-1xVEGF bispecific) with Datroway (datopotamab deruxtecan, a TROP2-directed ADC).
  • It starts with a Phase III study in first-line triple-negative breast cancer, with plans to expand to other settings including lung cancer.
  • The companies will share trial costs, and each retains development and commercial rights to its own drug.
PointsBased on public reports

Three companies, two assets, and no one gives up rights: this is a cost-sharing structure, not a licensing deal. For Summit, pairing ivonescimab with a validated TROP2 ADC borrows AstraZeneca and Daiichi's TNBC credibility and trial muscle. For the big partners, it is a cheap hedge on the PD-1xVEGF class. I would want to see the control arm and endpoints before judging how much it de-risks.